BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Pramanik SD, Kumar Halder A, Mukherjee U, Kumar D, Dey YN, R M. Potential of histone deacetylase inhibitors in the control and regulation of prostate, breast and ovarian cancer. Front Chem 2022;10:948217. [DOI: 10.3389/fchem.2022.948217] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
Number Citing Articles
1 Taurelli Salimbeni B, Corvaja C, Valenza C, Zagami P, Curigliano G. The triple negative breast cancer drugs graveyard: a review of failed clinical trials 2017-2022. Expert Opin Investig Drugs 2022;31:1203-26. [PMID: 36413823 DOI: 10.1080/13543784.2022.2151433] [Reference Citation Analysis]
2 Pellegrino M, Ricci E, Ceraldi R, Nigro A, Bonofiglio D, Lanzino M, Morelli C. From HDAC to Voltage-Gated Ion Channels: What's Next? The Long Road of Antiepileptic Drugs Repositioning in Cancer. Cancers (Basel) 2022;14:4401. [PMID: 36139561 DOI: 10.3390/cancers14184401] [Reference Citation Analysis]